Tests magnetic brain stimulation for treating Alzheimer's disease
Tests repeated magnetic brain stimulation in adults with Alzheimer's disease.
Key facts
- Who runs it
- Fujian Medical University Union Hospital
- Where
- Fuzhou, ChinaSee the site
- Trial code
- Registry title
- Efficacy and Safety of Transcranial Magnetic Stimulation in Treatment of Alzheimer's Disease
- Status
- Recruiting
- People taking part
- 81 people, planned
- Started
- 16 Apr 2025
- Expected to end
- 30 Apr 2029
- Type of study
- Interventional, 3 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- rTMS
- sham rTMS
- Accelerated rTMS
- Record updated
- 31 August 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 50 to 90 with mild to moderate Alzheimer's disease and lab or scan signs of Alzheimer's changes in the brain.
- Age
- 50 to 90 years
- Sex
- All sexes
- Disease stage
- Alzheimer's disease, mild to moderate (CDR Global Score 1 to 2)
- Biomarker or test result
- Signs of Alzheimer's disease: positive amyloid PET, or positive cerebrospinal fluid biomarkers, or positive plasma biomarkers
Main reasons for not taking part
- Contraindications to rTMS treatment
- Severe complications or immune diseases
- Unable to cooperate with study procedures
- History of epilepsy
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Meets the 2018 NIA-AA diagnostic criteria for Alzheimer's disease (AD)
- Meets DSM-5 diagnostic criteria
- Mild to moderate disease severity (CDR Global Score 1 to 2)
- Evidence of AD pathology: positive amyloid PET OR positive cerebrospinal fluid (CSF) AD biomarkers OR positive plasma AD biomarkers
Who cannot take part
- Severe complications or immune diseases
- History of epilepsy
- Contraindications to rTMS treatment
- Unable to cooperate with study procedures
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 50 and 90 years old?
Where in China
- rTMSFuzhou, ChinaContact: Xiaodong PanTaking people
About the trial
What the trial wants to find out
This study is grounded in the regulatory mechanisms of the glymphatic system and applies repetitive transcranial magnetic stimulation (rTMS) to the treatment of Alzheimer's disease (AD). The clinical efficacy and safety of rTMS will be systematically evaluated. Furthermore, transcranial magnetic stimulation-evoked potentials (TMS-EEG) and functional near-infrared spectroscopy (fNIRS) will be employed to investigate, from the perspectives of synaptic plasticity and neurovascular coupling, the mechanisms by which rTMS influences glymphatic function. Collectively, this work aims to provide new insights into both the therapeutic effectiveness and the underlying mechanisms of rTMS in AD.
The 3 groups in the trial
- rTMSTreatment being tested
- sham rTMSSham treatment, for comparison
- Accelerated rTMSExisting treatment, for comparison
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Efficacy and Safety of Repetitive Transcranial Magnetic Stimulation in the Treatment of Alzheimer's Disease and Exploration of Glymphatic Mechanisms
- Plain-language title
- Tests magnetic brain stimulation for treating Alzheimer's diseaseGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT07324161, who can take part
- Record updated
- 31 August 2026